Table V.
Patient profiles and tumor characteristics.
| Variable | Number of patients, n, (n=940) | Percentage of patients, % |
|---|---|---|
| Host factor | ||
| Age, years (mean ± standard error) | 64.2±0.28 | |
| Sex (male/female) | 723/217 | (76.9/23.1) |
| HBs Ag (positive/negative/unknown) | 168/755/17 | (17.9/80.3/1.8) |
| HCV Ab (positive/negative/unknown) | 627/305/8 | (66.7/32.4/0.9) |
| Bilirubin, mg/dl (mean ± standard error) | 0.81±0.01 | |
| Albumin, g/dl (mean ± standard error) | 3.86±0.04 | |
| Prothrombin time, % (mean ± standard error) | 84.3±0.42 | |
| ICG-R15, % (mean ± standard error) | 17.9±0.35 | |
| Platelet count, ×103/mm3 (mean ± standard error) | 15.3±0.26 | |
| Degree of liver damage (A/B) | 651/289 | (69.3/30.7) |
| Child-Pugh classification (A/B) | 865/75 | (92.0/8.0) |
| ALBI grade (A/B) | 548/392 | (58.3/41.7) |
| Tumor factor | ||
| Tumor maximum diameter, cm (<2/>2, <5/≥5) | 182/586/172 | (19.4/62.3/18.3) |
| Number of tumors (1/2-3/≥4) | 732/188/20 | (77.9/20.0/2.1) |
| NxS factor (<4/4-9/>9) | 523/309/108 | (55.6/32.9/11.5) |
| Macroscopic portal vein invasion (absent/present/unknown) | 885/39/16 | (94.1/4.1/1.7) |
| Macroscopic hepatic vein invasion (absent/present/unknown) | 931/6/3 | (99.0/0.6/0.3) |
| Microscopic portal vein invasion (absent/present) | 302/638 | (32.1/67.9) |
| Microscopic hepatic vein invasion (absent/present) | 899/41 | (95.6/4.4) |
| AFP, ng/ml (<400/≥400) | 761/179 | (81.0/19.0) |
| DCP, mAU/ml (<1,000/>1,000/unknown) | 713/164/63 | (75.9/174.5/6.7) |
| Differentiation (well/moderate/poor/unknown) | 134/575/211/20 | (14.3/61.2/22.4/2.1) |
| Anatomical resection (yes/no) | 466/474 | (49.6/50.4) |
| Recurrence (yes/no) | 714/226 | (76.0/24.0) |
| Death (yes/no) | 576/364 | (61.3/38.7) |
| TNM Stage, LCSGJ 5th (I/II/III/IV) | 165/383/325/67 | (17.6/40.7/34.6/7.1) |
| TNM Stage, AJCC 8th (IA/IB/II/III/IVA) | 197/325/360/56/2 | (21.0/34.6/38.3/6.0/0.2) |
| Staging systems | ||
| MITS-CP model (0/1/2/3) | 483/324/123/10 | (51.4/34.5/13.1/1.1) |
| MITS-LD model (0/1/2/3) | 367/366/173/34 | (39.0/39.0/18.4/3.6) |
| MITS-ALBI model (0/1/2/3) | 214/437/231/58 | (22.8/46.5/24.6/6.2) |
| JIS score (0/1/2/3/4) | 151/364/337/81/7 | (16.1/38.7/35.9/8.6/0.7) |
| Modified JIS score (0/1/2/3/4) | 116/316/340/145/23 | (12.3/33.6/36.2/15.4/2.4) |
| ALBI-T score (0/1/2/3/4) | 67/261/351/225/36 | (7.1/27.8/37.3/23.9/3.8) |
| Tokyo score (0/1/2/3/4) | 97/376/342/112/13 | (10.3/40.0/36.4/11.9/1.4) |
| CLIP (0/1/2/3/4/5) | 439/323/119/43/11/5 | (46.7/34.4/12.7/4.6/0.5) |
| BCLC (0/A/B/C) | 144/661/96/39 | (15.3/70.3/10.2/4.1) |
AFP, α-fetoprotein; ALBI-T, Albumin-Bilirubin grade with TNM; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; HBs Ag, hepatitis B surface antigen; HCV Ab, hepatitis C virus antibody; ICG-R15, indocyanine green retention rate at 15 min; JIS, Japan Integrated Staging score; LCSGJ, Liver Cancer Study Group of Japan; MITS-CP, mathematical integrated model for tumor staging with the Child-Pugh classification; MITS-LD, mathematical integrated model for tumor staging with the degree of liver damage classification, MITS-ALBI, mathematical integrated model for tumor staging with Albumin-Bilirubin grade; NxS, tumor number and size; TNM, tumor-lymph node-metastasis; UICC, Union for International Cancer Control.